Merck KGaA, Darmstadt, Germany, announced on June 30, 2025, that it has closed the acquisition of SpringWorks Therapeutics, Inc. The transaction was completed for an enterprise value of $3.4 billion, following regulatory clearances and the fulfillment of other customary closing conditions.
The definitive agreement for this acquisition was initially announced on April 28, 2025. This marks one of the largest M&A deals in the global biopharma sector for 2025, integrating SpringWorks' rare tumor portfolio into Merck KGaA's Healthcare business.
Upon closing, SpringWorks’ shares will no longer be traded on the Nasdaq, and shareholders received $47 per share in cash. The business combination is expected to immediately contribute to Merck KGaA’s revenues and be accretive to its earnings per share pre (EPS pre) by 2027.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.